Toxic multinodular goiter primary prevention

Toxic multinodular goiter Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Toxic multinodular goiter from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Toxic multinodular goiter primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Toxic multinodular goiter primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Toxic multinodular goiter primary prevention
CDC on Toxic multinodular goiter primary prevention
Toxic multinodular goiter primary prevention in the news
Blogs on Toxic multinodular goiter primary prevention
Directions to Hospitals Treating Toxic multinodular goiter
Risk calculators and risk factors for Toxic multinodular goiter primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

• There are no established measures for the primary prevention of [disease name].
• There are no available vaccines against [disease name].

OR

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
• [Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

• There are no established measures for the primary prevention of [disease name].
• There are no available vaccines against [disease name].

OR

• Effective measures for the primary prevention of [disease name] include:
  • [measure1]
  • [measure2]
  • [measure3]

OR

• [Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
  • [strategy 1]
  • [strategy 2]
  • [strategy 3]